Skip to main content

Table 1 Patient and tumor characteristics

From: IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer

 

FBLAD-U95 set

FBLAD-Exon set

Patients

n = 75

n = 125

 Sex

  Male, n (%)

61 (81.3)

100 (80.0)

  Female, n (%)

14 (18.7)

25 (20.0)

 Mean age at surgery, years ± SD

62.8 ± 13.8

69.7 ± 15.2

 Mean follow-up, months ± SD

40.1 ± 40.0

33.6 ± 29.7

Bladder tumors

 Clinical presentation

  Incident tumors, n (%)

58 (77.3)

107 (85.6)

  Recurrent tumors, n (%)

17 (22.7)

18 (14.4)

 TNM 2009 Stage

  Ta, n (%)

24 (32.0)

24 (19.2)

  T1, n (%)

12 (16.0)

32 (25.6)

   T ≥ 2, n (%)

39 (52.0)

69 (55.2)

 WHO 1973 Grade

  G1, n (%)

11 (14.7)

5 (4.0)

  G2, n (%)

23 (30.7)

26 (20.8)

  G3, n (%)

41 (54.7)

94 (75.2)